Industry Insights
-
Pursuing Venture Philanthropy With Opus Genetics: The Business Of Biotech
8/10/2022
Explore new, more agile approaches to overcoming the advanced therapy obstacles inherent to bringing rare disease treatments to market.
-
Upskilling Your Quality Team For The AI Revolution In Pharma 4.0
3/21/2025
While AI systems offer advanced capabilities for data analysis, process optimization, and quality assessments, your quality team must first be proficient in interacting with them.
-
7 Key Concepts In The FDA's Quality System Guidance For Pharma
3/4/2022
Here are some key concepts that the FDA deems critical for a discussion on modern quality systems and defines them within the scope of pharma manufacturing.
-
Importance Of Process Safety In Fluid Management Of ADCs
11/22/2022
Learn more about the application of ADCs, the challenges of manufacturing them, and tools for handling them in closed systems without exposing them to the environment.
-
Are We Witnessing A New "Age Of The CDMO"?
12/3/2024
Over the past few years, the pharma/biotech industry has seen a significant shift from internal to external manufacturing. This article examines the driving factors and the author's perspective for what to expect in 2025 and beyond.
-
Trends In Bioprocessing CDMO Selection
Learn which CDMO characteristics experienced outsourcers value most from ISR’s Bioprocessing Market Trends and Outsourcing Dynamics report.
-
5 Reasons To Move From Shake Flasks To A Bioreactor
11/14/2023
Find out how a bench-scale bioreactor could pave your way to maximum culture density, better process information, and scale-up/scale-down development.
-
Lessons Learned From Implementing FDA CSA Guidance
2/20/2024
Explore how some drug manufacturers are using the latest Computer Software Assurance (CSA) guidance to reduce effort and cost and the bumps you may hit along the way.
-
Aiming To Solve The 3 Key Challenges Of CAR T-Cell Manufacturing
1/18/2022
These authors share their best practices for solving the three key challenges of CAR T-cell manufacturing (supply constraints, scalability issues, and storage and logistics challenges) using their experiences with Epstein Barr Virus (EBV) T cells.
-
Risk vs. Resilience: Striking A Balance In The Biopharma Supply Chain
4/5/2022
What are the biggest vulnerabilities in today’s biopharmaceutical supply chain, and what can suppliers to do address them?